Similar articles

• Lack of efficacy of neutral endopeptidase inhibitor ecadotril in heart failure. The International Ecadotril Multi-centre Dose-ranging Study Investigators.

  Cleland JG, Swedberg K. Cleland JG, et al. Lancet. 1998 May 30;351(9116):1657-8. doi: 10.1016/s0140-6736(05)77712-6. Lancet. 1998. PMID: 9620738 Clinical Trial. No abstract available.
• [The new class of drugs-- metalloprotease inhibitors -- in the treatment of heart failure].

  Berezin AE. Berezin AE. Klin Med (Mosk). 2004;82(5):7-15. Klin Med (Mosk). 2004. PMID: 15230033 Review. Russian. No abstract available.
• Ecadotril. (S)-acetorphan, sinorphan.

  [No authors listed] [No authors listed] Drugs R D. 1999 Apr;1(4):343-5. doi: 10.2165/00126839-199901040-00014. Drugs R D. 1999. PMID: 10566059 No abstract available.
• Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension.

  Tunny TJ, Ziesak MD, Armstrong R, Klemm SA, Stowasser M, Finn WL, Gordon RD. Tunny TJ, et al. J Hypertens Suppl. 1993 Dec;11(5):S222-3. J Hypertens Suppl. 1993. PMID: 8158355 Clinical Trial. No abstract available.
• [Omapatrilat for treatment of heart failure].

  Yamazaki T. Yamazaki T. Nihon Rinsho. 2007 May 28;65 Suppl 5:173-5. Nihon Rinsho. 2007. PMID: 17571381 Review. Japanese. No abstract available.